Athersys Future Hinges on Stem Cell Stroke Study Results

Athersys' future arguably hinges on the results of this mid-stage study. The company's stock price plunged last April when MultiStem, the stem cell therapy, failed to benefit ulcerative colitis patients.

http://www.thestreet.com/story/13108577/1/athersys-future-hinges-on-stem-cell-stroke-study-results.html?cm_ven=RSSFeed&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+tsc%2Ffeeds%2Frss%2Flatest-stories+%28TheStreet.com+Latest+Headlines%29